HHS in­spec­tor gen­er­al rais­es con­cerns over three FDA ac­cel­er­at­ed ap­provals

The up­heaval over the FDA’s ac­cel­er­at­ed ap­proval of Bio­gen’s now-pulled Alzheimer’s drug Aduhelm in 2021 led HHS’ Of­fice of In­spec­tor Gen­er­al to re­view 24 oth­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER